Search

Displaying results 4821 - 4830 of 5383 in total
  1. Drug

    Ty800

    go.drugbank.com/drugs/DB04989
    Investigational

    It is being developed by AVANT Immunotherapeutics, Inc.

  2. Drug

    GS030-DP

    go.drugbank.com/drugs/DB17847
    Investigational

    It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector.

  3. Drug

    AC-003

    go.drugbank.com/drugs/DB22691
    Investigational

    [L53458,L53463] By inhibiting RIPK1 kinase activity, AC-003 thereby inhibits RIPK1-mediated cell death and inflammation.

  4. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    Vonicog alfa is a recombinant human von Willebrand factor (rVWF) produced from Chinese hamster ovary cells. Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF, which is a critical plasma glycop...

  5. Drug

    Metipranolol

    go.drugbank.com/drugs/DB01214
    ApprovedWithdrawn

    A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

  6. Drug

    Norethindrone enanthate

    go.drugbank.com/drugs/DB14678
    Investigational

    Categories: Hormonal Contraceptives for Systemic Use
  7. Drug

    Solithromycin

    go.drugbank.com/drugs/DB09308
    Investigational

    Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Talniflumate

    go.drugbank.com/drugs/DB09295
    Investigational

    Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this

  9. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment

  10. Drug

    Afimoxifene

    go.drugbank.com/drugs/DB04468
    Investigational

    It is being developed by Ascent Therapeutics.